# Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

> **NCT06302569** · PHASE2 · RECRUITING · sponsor: **Giuseppe Procopio** · enrollment: 23 (estimated)

## Conditions studied

- Bellini Carcinoma
- Collecting Duct Carcinoma
- Renal Medullary Carcinoma

## Interventions

- **DRUG:** Pembrolizumab + Enfortumab Vedotin

## Key facts

- **NCT ID:** NCT06302569
- **Lead sponsor:** Giuseppe Procopio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2027-10
- **Final completion:** 2029-05
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06302569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06302569, "Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06302569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*